RT Journal Article
SR Electronic
T1 Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260928
DO 10.1101/2021.07.21.21260928
A1 Madelon, Natacha
A1 Lauper, Kim
A1 Breville, Gautier
A1 Royo, Irène Sabater
A1 Goldstein, Rachel
A1 Andrey, Diego O.
A1 Grifoni, Alba
A1 Sette, Alessandro
A1 Siegrist, Claire-Anne
A1 Finckh, Axel
A1 Lalive, Patrice H.
A1 Didierlaurent, Arnaud M.
A1 Eberhardt, Christiane S.
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.21.21260928.abstract
AB Patients treated with anti-CD20 therapy are particularly at risk of developing severe COVID-19, however little is known regarding COVID-19 vaccine effectiveness in this population. This study assesses humoral and T-cell responses to mRNA-based COVID-19 vaccines in patients treated with rituximab for rheumatic diseases or ocrelizumab for multiple sclerosis (n=37), compared to immunocompetent individuals (n=22). SARS-CoV-2-specific antibodies were detectable in only 69.4% of patients and at levels that were significantly lower compared to controls who all seroconverted. In contrast to antibodies, Spike (S)-specific CD4+ T cells were equally detected in immunocompetent and anti-CD20 treated patients (85-90%) and mostly of a Th1 phenotype. Response rates of S-specific CD8+ T cells were higher in ocrelizumab (96.2%) and rituximab-treated patients (81.8%) as compared to controls (66.7%). Vaccine-specific CD4+ and CD8+ T cells were polyfunctional but expressed more IL-2 in patients than in controls. In summary, our study suggests that patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA COVID-19 vaccines, despite impaired humoral responses. This could play an important role in the prevention of severe COVID-19.Competing Interest StatementA.S. is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. A.D. is consultant for Speranza. All of the other authors declare no competing interests. LJI has filed for patent protection for various aspects of vaccine design and identification of specific epitopes.Funding StatementThis work was supported by the HUG private Foundation, the NIH NIAID contract no. 75N9301900065 and by the Giorgi-Cavaglieri foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective observational study was conducted at the Geneva University Hospitals (HUG), Switzerland according to the principles of Good Clinical Practice and was approved by the Geneva Cantonal Ethics Commission (2021-00430).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in text, figures or as supplementary material. Raw data files (anonymized data)included in this manuscript may be available upon request to the authors.